Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Ivabradine

Mirembe Reed, Preeti Patel, Diala Nicolas  1
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Ivabradine

Mirembe Reed et al.
Free Books & Documents

Excerpt

Ivabradine is FDA-approved for patients with stable heart failure and an ejection fraction of 35% or less to reduce the risk of hospitalization due to worsening heart failure. By selectively inhibiting the I(f) current in the sinoatrial node, ivabradine lowers heart rate without affecting myocardial contraction, relaxation, or ventricular repolarization. Reducing resting heart rate is a therapeutic strategy to mitigate adverse cardiovascular outcomes, particularly in patients with left ventricular dysfunction. This activity reviews ivabradine’s indications, administration, contraindications, and precautions to optimize clinical decision-making.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Mirembe Reed declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Diala Nicolas declares no relevant financial relationships with ineligible companies.

References

    1. Krajcirovicova K, Aziriova S, Baka T, Repova K, Adamcova M, Paulis L, Simko F. Ivabradine does not impair anxiety-like behavior and memory in both healthy and L-NAME-induced hypertensive rats. Physiol Res. 2018 Dec 31;67(Suppl 4):S655-S664. - PubMed
    1. Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H. Ivabradine for the Treatment of Cardiovascular Diseases. Circ J. 2019 Jan 25;83(2):252-260. - PubMed
    1. Sathyamurthy I, Newale S. Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications. Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S435-S441. - PMC - PubMed
    1. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW, ACC/AHA Joint Committee Members 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 03;145(18):e895-e1032. - PubMed
    1. Waranugraha Y, Rizal A, Tjahjono CT, Vilado IY, David NI, Abudan F, Setyaningrum DA. A Systematic Review and Meta-Analysis of Randomised Controlled Trials Assessing Clinical and Haemodynamic Outcomes of Ivabradine in Heart Failure With Reduced Ejection Fraction Patients. Heart Lung Circ. 2024 Jul;33(7):962-974. - PubMed

Publication types

LinkOut - more resources